login
Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

Revivent Myocardial Anchoring System for left ventricle restoration gets the CE mark


Tuesday, 04 Dec 2012 13:24
Revivent Myocardial Anchoring System. Courtesy: BioVentrix
Revivent Myocardial Anchoring System. Courtesy: BioVentrix

BioVentrix has received the CE mark for its Revivent Myocardial Anchoring System, which makes possible less invasive ventricular enhancement (LIVE), a procedure that restores the left ventricle from damage done by a heart attack to a more optimal volume and conical shape, thereby enhancing performance of the heart’s non-damaged myocardium and improving quality of life.


Reshaping of the left ventricle is usually performed with surgical ventricular restoration (SVR), a procedure that requires stopping the beating heart and supporting it with cardiopulmonary bypass, while significant incisions into the heart muscle are made to excise the scarred, ischaemic ventricular tissue. The invasive nature of SVR limits the number of patients for whom the procedure may be performed due to the fragile nature of this patient population. The company states that, in contrast, the less invasive LIVE procedure using the Revivent system is performed without the need of cardiopulmonary bypass or making incisions into the heart.

“Heart failure in Europe is more common than most cancers,” said Louis Labrousse,professor of Cardiovascular Surgery at Hopital Haut-Lévêque, Bordeaux-Pessac, France. “Prior to the availability of Revivent, open-heart surgery could only be applied sparingly among this very fragile patient population due to its invasiveness. There are some 14 million people in Europe who currently suffer from heart failure. Unfortunately, this number is expected to more than double by 2020. Thus, regulatory approval of Revivent is significant news for ischaemic heart failure patients throughout Europe.”


“Because of Revivent, the LIVE procedure can be performed without cardiopulmonary bypass: therefore the heart is beating and stable, and there is no major surgical incision in the myocardium,” said Andrews S Wechsler, professor of Cardiothoracic Surgery, Drexel University College of Medicine, Philadelphia, USA. “Intraoperative monitoring has documented the excellent haemodynamics present at the end of the LIVE procedure without vasoactive support. No doubt, regulatory approval of Revivent will have a significant impact on the treatment of heart failure patients in Europe going forward.”


“Our innovative Revivent system used during LIVE procedures will empower cardiac surgery teams not only to ensure optimal clinical outcomes and enhance quality of life for heart failure patients but also to minimise risk compared to the previous gold standard of conventional left ventricle reconstruction surgery,” said Kenneth Miller, president and chief executive officer of BioVentrix. “While we are extremely pleased with the regulatory approval of Revivent in Europe, we are also looking forward to our next-generation Revivent technology―transcatheter ventricular restoration (TCVR),” added Miller. “Given the successful clinical outcomes we have achieved with Revivent, we have fast-forwarded development of our next-gen, endovascular technology designed to achieve the same results as the LIVE procedure, but with a sternal-sparing technique. This closed-chest, beating heart, transcatheter therapy is expected to be a new paradigm for treating heart failure patients, holding great promise for those who have suffered a heart attack but are just too sick to tolerate invasive heart surgery.”


About LIVE


The Less invasive ventricular enhancement (LIVE) therapy is an innovative, new off-pump procedure that helps restore the left ventricle’s intrinsic functional efficiency, rather than relying on a surrogate pumping device or other invasive treatment. The only therapy currently designed to restore optimal left ventricle size and function, LIVE provides physician teams with a gentler surgical option that enables them to more confidently treat heart failure patients who may not tolerate left ventricle incisions. LIVE fills the gap in available heart failure treatments, offering the potential for more consistent and favorable surgical outcomes, while giving heart failure patients and their families renewed hope for a more productive life.




Add New Comment

Most popular


Abbott to acquire St Jude Medical
Tuesday, 03 May 2016
Abbott is set to acquire St Jude Medical, expanding its portfolio to cover cardiovascular markets such as atrial fibrillation, structural heart and heart failure as well as neuromodulation. The ... Abbott to acquire St Jude Medical

European Union agrees new rules for approving medical devices and in vitro diagnostic medical devices
Tuesday, 31 May 2016
The Netherlands presidency of the European Council and representatives of the European Parliament have reached a political agreement on two draft regulations for medical devices. The new regulations ... European Union agrees new rules for approving medical devices and in vitro diagnostic medical devices

Young female acute coronary syndrome patients have significantly greater comorbidities than their male counterparts
Wednesday, 11 May 2016
A study indicates that women aged less than 55 years with acute coronary syndrome undergoing percutaneous coronary intervention (PCI) have significantly greater comorbidities and worse outcomes than ... Young female acute coronary syndrome patients have significantly greater comorbidities than their male counterparts

Features


Trials on newer generation drug-eluting stents in small coronary vessels needed
Monday, 27 Jun 2016
A network meta-analysis of early generation, drug-eluting stents, bare metal stents, drug-coated balloons, and balloon angioplasty indicate that sirolimus-eluting stents are associated with the most ... Trials on newer generation drug-eluting stents in small coronary vessels needed

Online medical information: A blessing or a curse?
Thursday, 23 Jun 2016
The internet age has enabled patients to access a plethora of medical information. However, a potential drawback is that some of this information is inaccurate or misleading—causing unnecessary ... Online medical information: A blessing or a curse?

Profiles


James Blankenship
Wednesday, 08 Jun 2016
James Blankenship is the 2015–2016 president of SCAI and has been involved with designing and ... James Blankenship

Alexandra Lansky
Monday, 07 Mar 2016
Alexandra Lansky (Director, Heart and Vascular Clinical Research Program, Yale University School of ... Alexandra Lansky

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions